LatticeMLS
Menu

Module HEME-16 · Version 1.0

How Hemoglobin Analysis Methods Work

Compare the evidence produced by major hemoglobin analysis methods, recognize method limits, and select a bounded confirmatory action.

Your next section

Start section 1

Read without an account. Sign in to save.

Who this module is for

Medical laboratory learners who have completed basic protein separation and need a foundation for reviewing hemoglobin fractionation patterns.

Learning objectives

  • Compare separation and detection principles across major hemoglobin methods.
  • Identify method-specific zones or windows and common co-elution or co-migration limits.
  • Use a second method and clinical and CBC context to resolve presumptive patterns.

How completion works

Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.

Sources

10 sources

  1. 1. Wajcman H, Moradkhani K. Abnormal haemoglobins: detection and characterization. Indian Journal of Medical Research. 2011;134:538-546.

    Source note · peer-reviewed literature

  2. 2. Old J, et al. Best practice recommendations. In: Prevention of Thalassaemias and Other Haemoglobin Disorders. NCBI Bookshelf. 2013.

    Source note · professional society guidance

  3. 3. Traeger-Synodinos J, Harteveld CL, Old JM, et al. EMQN Best Practice Guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies. European Journal of Human Genetics. 2015;23:426-437.

    Source note · professional society guidance

  4. 4. Clinical and Laboratory Standards Institute. NBS08: Newborn Screening for Hemoglobinopathies. 1st ed. 2019.

    Source note · consensus standard

  5. 5. Galanello R, Origa R. Newborn screening for haemoglobinopathies. NCBI Bookshelf. 2013.

    Source note · professional society guidance

  6. 6. Harteveld CL. The evolution of next-generation sequencing in screening and diagnosis of hemoglobinopathies. Frontiers in Physiology. 2021;12:686689.

    Source note · peer-reviewed literature

  7. 7. U.S. Food and Drug Administration. S510(k) Summary, VARIANT II TURBO HbA1c Kit 2.0, K142448.

    Source note · manufacturer labeling

  8. 8. U.S. Food and Drug Administration. CASGEVY (exagamglogene autotemcel) prescribing information.

    Source note · manufacturer labeling

  9. 9. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for graft rejection in children with non-malignant diseases after allogeneic stem cell transplantation. Blood. 2004;103:2339-2342.

    Source note · peer-reviewed literature

  10. 10. College of American Pathologists. Hematology and Coagulation Checklist, sample checklist item HEM.35984, Hb S Predominant Band.

    Source note · accreditation standard